Tech Center 1600 • Art Units: 1646 1674
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17470455 | BIOMARKERS AND METHODS FOR ASSESSING PSORIATIC ARTHRITIS DISEASE ACTIVITY | Final Rejection | The Regents of the University of California |
| 17771313 | COMPOSITIONS AND METHODS FOR MINIMIZING PROTEIN LOSS AT LOW PROTEIN CONCENTRATIONS | Final Rejection | AMGEN INC. |
| 18101310 | Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18045588 | ANTIBODIES TO HUMAN GDF8 | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17934259 | COMPOSITIONS AND METHODS FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18248280 | TREATMENT OF FLARES IN LUPUS | Non-Final OA | ASTRAZENECA AB |
| 18019052 | CST6, CELLS EXPRESSING CST6 AND METHODS OF USE | Non-Final OA | BioVentures, LLC |
| 18653312 | COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 17772042 | Immune Response Suppressant | Final Rejection | University of Tsukuba |
| 17995720 | MODIFIED KISSPEPTIN RECEPTOR AGONISTS FOR FATTY LIVER DISEASE | Non-Final OA | Rutgers, The State University of New Jersey |
| 17432177 | LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION | Non-Final OA | Rutgers, the State University of New Jersey |
| 17615959 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Final Rejection | Janssen Biotech, Inc. |
| 18028424 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES, COMPRISING TRIPLE AGONIST OR CONJUGATE THEREOF HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1 AND GLP RECEPTORS | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18319821 | Treatment of ENPP1 Deficiency and ABCC6 Deficiency | Non-Final OA | Inozyme Pharma, Inc. |
| 18248729 | MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | CYTIMM THERAPEUTICS, INC. |
| 17871180 | METHODS OF STIMULATING BONE GROWTH WITH ABALOPARATIDE AND DENOSUMAB | Non-Final OA | Radius Health, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy